Jason B. Daly - 03 Mar 2023 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role
SVP, Chief Legal Officer
Signature
/s/ Denis Butkovic, Attorney-in-Fact
Issuer symbol
AMRX
Transactions as of
03 Mar 2023
Net transactions value
-$15,675
Form type
4
Filing time
07 Mar 2023, 17:00:25 UTC
Previous filing
03 Mar 2022
Next filing
05 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMRX Class A Common Stock Options Exercise +22,645 22,645 03 Mar 2023 Direct F1, F2
transaction AMRX Class A Common Stock Tax liability $15,675 -8,164 -36% $1.92 14,481 03 Mar 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMRX Restricted Stock Units Options Exercise $0 -22,645 -25% $0.000000 67,935 03 Mar 2023 Class A Common Stock 22,645 Direct F2, F4
transaction AMRX Restricted Stock Units Award $0 +152,905 $0.000000 152,905 03 Mar 2023 Class A Common Stock 152,905 Direct F2, F5
transaction AMRX Performance-Based Restricted Stock Units Award $0 +305,810 $0.000000 305,810 03 Mar 2023 Class A Common Stock 305,810 Direct F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the gross number of shares of common stock issuable to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3 Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
F4 On March 3, 2022, the reporting person was granted 90,580 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F5 The restricted stock units vest in four equal annual installments beginning on March 3, 2024.
F6 Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F7 Represents a performance-based restricted stock unit grant of 152,905 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period.

Remarks:

Exhibit 24-Power of Attorney